Algernon Pharmaceuticals Inc (AGNPF)

[Diogenes of Sinope]

Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score...

Planning Phase II Trial

Vancouver, BC -- November 01, 2018 -- InvestorsHub NewsWire -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed positive results in a recently completed study investigating its therapeutic effects in the widely used STAM™ mouse model from SMC Laboratories. NP-160 is one of a number of already approved compounds that Nash Pharma has been screening for new therapeutic uses as part of its drug repurposing strategy.

Data from this study demonstrated statistically significant improvements in several key measures relevant to the development and progression of NASH including:

A 2.0 reduction in the NAFLD/NAS score vs controls (p<0.05)
A 42.0% reduction in fibrosis as measured by Sirius red staining (p<0.01)
In the same study, Telmisartan (a well accepted control in NASH studies) significantly reduced the NAS score by 2.0 points (p<0.05) and reduced fibrosis by 19.7% (not statistically significant)
No negative side effects were observed.
“The NASH market segment represents an enormous unmet medical need globally and there is a particular interest in compounds exhibiting anti-fibrotic activity,” said Christopher J. Moreau CEO of Nash Pharma. “We plan to present our preclinical in vivo NASH results at the upcoming 2nd Global NASH Congress, in February 2019 in London, UK and have now begun preparations to start a Phase IIa study for our repurposed lead candidate NP-160 in 2019.”

About NASH/NFLD

According to a new report published by Allied Market Research, “Global Opportunity Analysis and Industry Forecast, 2021-2025," the global NASH market was valued at $1.17 Billion in 2017, and is expected to reach $21.4 Billion by 2025, growing at a CAGR of 58.4% from 2021 to 2025. Currently, there are no US FDA approved treatments for NAFLD or NASH.

About Nash Pharmaceuticals Inc.

Nash Pharmaceuticals Inc. is a wholly owned subsidiary of Breathtec Biomedical Inc. Nash is a clinical stage pharmaceutical development company focused on drug repurposing in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Drug repurposing is the process of discovering new therapeutic uses for existing drugs.

For more information, visit https://nashpharmaceuticals.com/.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Nash Pharmaceuticals Inc.
604.398.4175 ext 701
[e-mail]
[e-mail]
www.breathtecbiomedical.com

https://ih.advfn.com/p.php?pid=nmona&article=78591111